BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 17159544)

  • 1. Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography.
    Szyszko T; Al-Nahhas A; Canelo R; Habib N; Jiao L; Wasan H; Pagou M; Tait P
    Nucl Med Commun; 2007 Jan; 28(1):15-20. PubMed ID: 17159544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and imaging experience with yttrium-90 microspheres in the management of unresectable liver tumours.
    Jiao LR; Szyszko T; Al-Nahhas A; Tait P; Canelo R; Stamp G; Wasan H; Lowdell C; Philips R; Thillainayagam A; Bansi D; Rubello D; Limongelli P; Woo K; Habib NA
    Eur J Surg Oncol; 2007 Jun; 33(5):597-602. PubMed ID: 17433608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging.
    Lewandowski RJ; Thurston KG; Goin JE; Wong CY; Gates VL; Van Buskirk M; Geschwind JF; Salem R
    J Vasc Interv Radiol; 2005 Dec; 16(12):1641-51. PubMed ID: 16371530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT.
    Bienert M; McCook B; Carr BI; Geller DA; Sheetz M; Tutor C; Amesur N; Avril N
    Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):778-87. PubMed ID: 15772860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. F-18 FDG PET/CT in the management of thyroid cancer.
    Iagaru A; Kalinyak JE; McDougall IR
    Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicentric phase II clinical trial on intra-arterial hepatic radiotherapy with 90yttrium SIR-spheres in unresectable, colorectal liver metastases refractory to i.v. chemotherapy: preliminary results on toxicity and response rates.
    Mancini R; Carpanese L; Sciuto R; Pizzi G; Golfieri R; Giampalma L; Cappelli A; Galaverni MC; Blotta A; Fiore F; Izzo F; Lastoria S; Mastro A; Di Marzo M; Cagol PP; Gasparini D; Geatti O; Bacchetti S; Pasqual E; Zeuli M; Paoletti G; Garufi C; Cosimelli M;
    In Vivo; 2006; 20(6A):711-4. PubMed ID: 17203751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
    De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
    J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer.
    Du Y; Cullum I; Illidge TM; Ell PJ
    J Clin Oncol; 2007 Aug; 25(23):3440-7. PubMed ID: 17592153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
    Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ
    J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STIR turbo SE MR imaging vs. coregistered FDG-PET/CT: quantitative and qualitative assessment of N-stage in non-small-cell lung cancer patients.
    Ohno Y; Koyama H; Nogami M; Takenaka D; Yoshikawa T; Yoshimura M; Ohbayashi C; Sugimura K
    J Magn Reson Imaging; 2007 Oct; 26(4):1071-80. PubMed ID: 17896365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. F18-FDG-PET evaluation of patients for resection of colorectal liver metastases.
    Huguet EL; Old S; Praseedom RK; Balan KK; Gibbs P; Jamieson NV
    Hepatogastroenterology; 2007 Sep; 54(78):1667-71. PubMed ID: 18019690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy.
    Jacene HA; Leboulleux S; Baba S; Chatzifotiadis D; Goudarzi B; Teytelbaum O; Horton KM; Kamel I; Macura KJ; Tsai HL; Kowalski J; Wahl RL
    J Nucl Med; 2009 Nov; 50(11):1760-9. PubMed ID: 19837757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
    Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
    Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.
    Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O
    Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.
    Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B
    J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraoperative sonography in patients with colorectal cancer and resectable liver metastases on preoperative FDG-PET-CT.
    Wildi SM; Gubler C; Hany T; Petrowsky H; Clavien PA; Jochum W; Gerlach T; Fried M; Mullhaupt B
    J Clin Ultrasound; 2008 Jan; 36(1):20-6. PubMed ID: 17937421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
    Wu ZJ; Zhang YX; Wei H; Jia Q
    Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose.
    Ceresoli GL; Chiti A; Zucali PA; Rodari M; Lutman RF; Salamina S; Incarbone M; Alloisio M; Santoro A
    J Clin Oncol; 2006 Oct; 24(28):4587-93. PubMed ID: 17008700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. State of the art: radiolabeled microspheres treatment for liver malignancies.
    Deleporte A; Flamen P; Hendlisz A
    Expert Opin Pharmacother; 2010 Mar; 11(4):579-86. PubMed ID: 20163269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.